Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments

PR Newswire August 8, 2017

TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology

PR Newswire July 18, 2017

TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer

PR Newswire June 27, 2017

TapImmune Inc. Enters into Definitive Agreements to Raise $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors

PR Newswire June 22, 2017

TapImmune to Present at 2017 Biotechnology Innovation Organization International Convention

PR Newswire June 14, 2017

TapImmune Provides First Quarter 2017 Corporate and Clinical Update

PR Newswire May 31, 2017

TapImmune to Provide First Quarter 2017 Business Update Conference Call and Webcast

PR Newswire May 18, 2017

Richard Kenney, MD, FACP, Joins TapImmune to Lead the Clinical Development Program

PR Newswire May 1, 2017

TapImmune Announces Change in Management and Board of Directors

PR Newswire April 28, 2017

NetworkNewsWire Announces Publication Highlighting Innovative Companies Developing Promising Cancer Treatments

Marketwired April 7, 2017

Global Oncology Market Gains Ground, Driven by Innovative Cancer Treatment Therapies

PR Newswire April 6, 2017

NetworkNewsWire Announces Publication of Discussion on the Potential of Immunotherapies for Cancer Treatment

Marketwired March 24, 2017

TapImmune to Participate in Two Upcoming Investor and Industry Conferences

PR Newswire March 22, 2017

TapImmune Provides Year End 2016 Corporate and Clinical Update

PR Newswire March 14, 2017

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

PR Newswire March 14, 2017

TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast

PR Newswire March 8, 2017

Immunotherapy Companies Leading the Charge for Treating Cancer

PR Newswire February 21, 2017

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

PR Newswire February 15, 2017

TapImmune, Inc. Presentation Now Available for On-Demand Viewing

PR Newswire February 9, 2017

TapImmune Expands Intellectual Property On PolyStart™ Platform For Use In Next-Generation T-Cell Vaccines

PR Newswire February 7, 2017